AUTHORS
Giuseppe Maiocco, M.D., Amanda Cashen, MD2, Sai Balasubramanian, MD, JD3, Amy Schneider4, Noupama Mirihagalle, M.D.5, Sarah S. Makhani, MD6, Suzanne R. Thibodeaux, MD7, Barbara J. Bryant, MD8, Cassandra Josephson, MD9, Elizabeth Crowe, MD, PhD10, Aaron Tobian, MD, PhD11, Jonathan R Day, PharmD, MD12, Shaji Kumar, MD13, Ruchika Goel, MD14
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Washington University in St. Louis, St. Louis, Missouri, United States
3 Southern Illinois University School of Medicine, Springfield, Illinois, United States
4 Southern Illinois University School of Medicine, Springfield, Illinois, United States
5 Southern Illinois University School of Medicine, Springfield, Illinois, United States
6 New York University Grossman School of Medicine, New York City, New York, United States
7 Washington University in St. Louis, St. Louis, Missouri, United States
8 Carter BloodCare, Bedford, Texas, United States
9 Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States
10 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
11 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
12 Mayo Clinic, Rochester, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Carter BloodCare, Bedford, Texas, United States, Southern Illinois University School of Medicine, Springfield, Illinois, United States
ABSTRACT
Background: Chimeric antigen receptor T-cell therapy (CAR-T) is a transformative intervention with expanding indications and utilization. However, CAR-T remains resource-intensive, and logistical and financial barriers threaten equitable access. We evaluated contemporary national sociodemographic disparities among inpatient CAR-T hospitalizations.
Methods: We performed a serial cross-sectional analysis over 5 years (2019-2023) of the National Inpatient Sample (NIS). CAR-T hospitalizations were identified using ICD-10-PCS codes. Survey-weighted estimates described payer mix, ZIP code-based patient income quartiles, race/ethnicity, geographic residence, and hospital bed size. Race/ethnicity and six-category urban-rural analyses were limited to 2019-2022; a binary metropolitan/non-metropolitan variable enabled five-year geographic analysis.
Survey-weighted logistic regression compared CAR-T hospitalizations against the entire NIS population as the reference, reported as unadjusted odds ratios [OR] (95% confidence intervals [CI]). Wald tests assessed categorical group effects, trend tests assessed ordered gradients, and characteristic-by-year interactions assessed changes over time. Analyses used Stata 18.0; P<0.05 was significant.
Results: From 2019-2023, an estimated 17,785 CAR-T hospitalizations occurred nationally, increasing 2.7-fold from 2,040 in 2019 to 5,585 in 2023. Compared with all NIS hospitalizations, CAR-T hospitalizations were disproportionately concentrated among a) privately insured patients (45.7% vs. 29.2%; OR(95% CI): 2.04(1.86-2.24); P<0.001), b) patients in the highest income quartile (33.8% vs. 20.0%; OR(95% CI): 2.05(1.80-2.33); P<0.001), c) White patients (71.8% vs. 63.7%; OR(95% CI): 1.45(1.25-1.69); P<0.001), d) metropolitan residents (87.5% vs. 84.5%; OR(95% CI): 1.28(1.10-1.49); P=0.001), and e) large-bed-size hospitals (74.5% vs. 49.2%; OR(95% CI): 3.02(2.19-4.17); P<0.001). Conversely, compared with all NIS hospitalizations, CAR-T hospitalizations were underrepresented among a) Medicaid-covered patients (8.0% vs. 22.9%; OR(95% CI): 0.22(0.19-0.26); P<0.001) and b) Black patients (7.3% vs. 15.6%; OR(95% CI): 0.41(0.35-0.49); P<0.001).
Across all study years, income quartiles and urban-rural residence for CAR-T versus all NIS hospitalizations were assessed across all categories, with the highest income quartile and large central metropolitan areas as respective reference groups. Compared with the highest income quartile, the odds of CAR-T hospitalization declined across the third quartile (OR(95% CI): 0.65(0.57-0.74)), second quartile (OR(95% CI): 0.51(0.44-0.59)), and lowest quartile (OR(95% CI): 0.34(0.29-0.41); P-trend<0.001). Compared with large central metropolitan patient residence, odds declined across small metropolitan (OR(95% CI): 0.74(0.58-0.94)), micropolitan (OR(95% CI): 0.76(0.60-0.97)), and rural areas (OR(95% CI): 0.69(0.51-0.93); P-trend<0.001).
Analyzing within CAR-T hospitalizations, payer composition shifted over the 5-year study period (Wald P-interaction=0.004): the Medicare proportion increased from 31.4% to 46.1% (P-trend<0.001), private insurance proportion decreased from 50.0% to 41.5% (P-trend=0.005), with the Medicaid share remaining persistently low (10.5% to 7.3%; P-trend=0.21). Income, racial, and geographic disparities did not change significantly across the 5-year study period (P-interaction: income quartile=0.32; race/ethnicity=0.95; geography=0.67).
Conclusions: Inpatient CAR-T administration expanded nationally from 2019-2023, but marked sociodemographic differences in representation persisted. CAR-T hospitalizations were disproportionately concentrated among privately insured, higher-income, metropolitan, White, and large-bed-size hospitalizations, with lower odds among Black, Medicaid-covered, lower-income, and non-metropolitan patients. Apart from increased Medicare coverage share, there was no evidence that socioeconomic, racial, and geographic inequities narrowed over time.
Because CAR-T infusion is the endpoint of a multistep preparatory pathway, these persistent differences likely reflect cumulative barriers in healthcare equity and a need to democratize CAR-T access. Notably, these data are limited to inpatient CAR-T infusion and may not reflect patterns in increasingly common outpatient CAR-T administration. Further study is needed to identify where these barriers arise and to inform interventions that improve equitable CAR-T delivery.
DISCLOSURES
Giuseppe Maiocco, M.D.: No relevant conflicts of interest to declare.